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ABSTRACT
Objective: Correlates of systemic lupus erythematosus
(SLE) Responder Index (SRI) response with clinical trial
end points were examined using pooled data from the
Study of Belimumab in Subjects with SLE (BLISS) trials
(N=1684).
Methods: Changes in clinical, laboratory and healthrelated quality of life measures from baseline at 52 weeks
were compared between SRI responders (n=761) and
non-responders (n=923).
Results: More SRI responders than non-responders had
≥4-point (100% vs 3.8%) and ≥7-point (40.3% vs
1.3%) Safety of Estrogens in Lupus Erythematosus
National Assessment-Systemic Lupus Erythematosus
Disease Activity Index reductions, no new British Isles
Lupus Assessment Group (BILAG) A and ≤1 new B
scores (91.9% vs 35.9%), and a 25% reduction in
corticosteroid dose decrease of 25% from >7.5 mg/d to
≤7.5 mg/d (25.5% vs 13.9%), and fewer had a
corticosteroid increase from ≤7.5 mg/d to >7.5 mg/d
(4.1% vs 21.3%; all p<0.001). More responders than
non-responders had improved organ domains: Safety of
Estrogens in Lupus Erythematosus National AssessmentSystemic Lupus Erythematosus Disease Activity Index
(mean 1.45 vs 0.40), BILAG (2.00 vs 0.39), and greater
improvement in Physician’s Global Assessment (all
p<0.001). Risks for developing any SLE flare or severe
flare were reduced in responders by 42% and 87%,
respectively (p<0.001). Responders reported greater
improvements in Medical Outcomes Survey Short Form
version 2 Physical and Mental Components and all
domain scores, and Functional Assessment of Chronic
Illness Therapy-Fatigue score compared with nonresponders (all p<0.001).
Conclusion: Overall, SRI response in patients with
active, autoantibody-positive SLE was associated with
improvements in clinical, laboratory and patient-reported
outcome measures, indicating that SRI response was
associated with a global benefit.
Trial registration number: NCT00424476;
NCT00410384.

KEY MESSAGES
▸ SRI responders reported greater improvements
from baseline in a range of clinical, laboratory
and health-related quality of life measures, compared with non-responders.
▸ SRI responses, irrespective of therapy, were
associated with global benefits in patients with
active, autoantibody-positive SLE.

INTRODUCTION
Systemic lupus erythematosus (SLE) is a
chronic autoimmune disease associated
with considerable morbidity, increased
mortality and poor health-related quality
of life (HRQoL).1 2 Belimumab is a
human immunoglobulin (Ig)-G1λ monoclonal antibody that inhibits the biological
activity of soluble B lymphocyte stimulator,
an immunomodulatory cytokine involved
in B cell selection and survival that is overexpressed in SLE.3 In two placebocontrolled trials conducted in patients with
active, autoantibody-positive SLE (Study of
Belimumab
in
Subjects
with
SLE
(BLISS)-52 and BLISS-76), belimumab
plus standard SLE therapy resulted in signiﬁcantly higher SLE Responder Index
(SRI) response rates at 1 year compared
with standard therapy ( placebo), indicating greater reductions in SLE disease activity with treatment4 5 and improvements in
HRQoL measures.6
The SRI is a novel composite end point
that requires improvement in SLE disease
activity without worsening in speciﬁc organ
domains or global disease activity7 consistent with US Food and Drug Administration
guidance for development of products for
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treatment of SLE.8 A SRI response requires clinically
meaningful improvement in the Safety of Estrogens in
Lupus Erythematosus National Assessment-SLE Disease
Activity Index (SELENA-SLEDAI) and no worsening of
disease, as measured by British Isles Lupus Assessment
Group (BILAG) organ domain score and Physician’s
Global Assessment (PGA). The present post hoc analysis examined the association of SRI response at Week
52, irrespective of treatment assignment, with individual clinical and laboratory measures, and patientreported HRQoL and fatigue among SRI responders
and non-responders.

MATERIALS AND METHODS
Patients with SLE (n=1684) who were autoantibodypositive (antinuclear antibody titre ≥1:80 and/or
antidouble-stranded DNA (anti-dsDNA) ≥30 IU/mL)
with a SELENA-SLEDAI score ≥6 received placebo,
belimumab 1 mg/kg or 10 mg/kg in addition to standard SLE therapy for 52 weeks (BLISS 52; NCT00424476)
or 76 weeks (BLISS 76; NCT00410384).4 5 Doses of
standard therapy were required to be stable for ≥30 days
prior to enrolment. Patients could not have severe active
lupus nephritis or severe active central nervous system
SLE. Progressive restrictions on immunosuppressives
and antimalarials began at treatment Week 16, and
restrictions on corticosteroids began at treatment Week
24.
Patients
were
stratiﬁed
at
screening
by SELENA-SLEDAI score (6–9 vs ≥10), proteinuria
(<2 g/24 h vs ≥2 g/24 h), and race (African descent or
indigenous American vs other). SRI response rate at
Week 52 was the primary end point, deﬁned as a
decrease of ≥4 points in SELENA-SLEDAI score, no new
BILAG A score and ≤1 new B score, and no worsening
(<0.3-point increase) in PGA score. Patients were considered non-responders if they did not meet SRI response
criteria, withdrew before Week 52 or received protocolprohibited medications.
The BLISS trials were conducted according to the
principles of the Declaration of Helsinki and the appropriate ethical approvals were obtained.4 5
Fifty-two-week data from BLISS-52 and BLISS-76 were
pooled.4 5 Of the 1684 patients enrolled, 761 were SRI
responders and 923 were non-responders at Week 52.
Clinical variables examined included the individual components of SRI response, the numbers of BILAG and
SELENA-SLEDAI organ domains with improvement,9 the
proportions of patients with ﬂares and severe ﬂares based
on the modiﬁed SLE Flare Index (SFI),10–12 and changes
in corticosteroid dose. Laboratory values consisted of
changes in anti-dsDNA, complement (C3 and C4), and
circulating B (CD20) cells. HRQoL, Medical Outcomes
Survey Short Form version 2 (SF-36 v2), and fatigue
(Functional Assessment of Chronic Illness Therapy
(FACIT)-Fatigue questionnaire) were examined.
Comparisons between responders and nonresponders for SELENA-SLEDAI and BILAG scores,
2

changes in corticosteroid dose, and normalisation of
anti-dsDNA, C3, and C4 biomarkers were performed
using the likelihood ratio test. The two-sample t test
was used to compare the improved SELENA-SLEDAI or
BILAG organ domains and per cent changes in PGA.
The Cox proportional hazards model was used to
compare risk of SFI ﬂares. Changes in FACIT-Fatigue
score and SF-36 physical component summary (PCS)
and mental component summary (MCS) and domain
scores were analysed using an analysis of covariance
model adjusted for baseline scores. Comparisons of per
cent changes from baseline in anti-dsDNA, C3, C4 and
CD20 B cells used the Wilcoxon test. No multiple test
adjustments were made for the above analyses, as they
were considered exploratory. The analyses were performed using SAS software V.9.2 or higher and
R statistical software V.1.9.1.
To examine the robustness of the univariate analysis,
baseline covariate adjusted analyses were performed to
assess baseline differences and the association with
responder status at Week 52. For clinical and serological
measures, the independent variables included the baseline value and SRI response status at Week 52. The
dependent variable was the change from baseline in the
clinical or serological measure.
RESULTS
SRI responses in patients receiving placebo, and
belimumab 1 and 10 mg/kg plus standard therapy were
38.8%, 46.2% ( p=0.006) and 50.6% ( p<0.001), respectively, at Week 52. Baseline characteristics were balanced
across treatment groups (table 1) and were generally
similar between SRI responders and non-responders.
Responders were more likely to have higher disease
activity, less serological activity (based on anti-dsDNA
titre ( p<0.001) and percentage of patients with C3 or
C4 levels less than the lower limits of normal ( p<0.001
and p<0.0001, respectively)), and were more likely to
have received a corticosteroid dose >7.5 mg/d ( p<0.01),
but not an immunosuppressant ( p<0.0001). At baseline,
there were no statistically signiﬁcant differences in B cell
subsets or plasma cell subsets (data not shown).13
Clinical and serological measures of disease activity
Clinical and laboratory measures of disease activity at
Week 52 are shown in table 2.
SRI components: SELENA-SLEDAI, BILAG and PGA
More responders than non-responders achieved a
≥4-point reduction in SELENA-SLEDAI score, with only
3.8% of non-responders meeting this SRI criterion
versus 100% of responders ( p<0.001) (table 2). A reduction of ≥7 in SELENA-SLEDAI score occurred in 40.3%
of responders versus 1.3% of non-responders ( p<0.001)
at Week 52. Mean numbers of improved organ domains
per patient were higher among responders as assessed
by SELENA-SLEDAI and BILAG (all p<0.001). Mean

Furie R, Petri MA, Strand V, et al. Lupus Science & Medicine 2014;1:e000031. doi:10.1136/lupus-2014-000031

Epidemiology and outcomes
Table 1 Baseline characteristics of BLISS-52 and BLISS-76 SRI responders and non-responders
Demographics
Women, n (%)
Mean age±SD, y
Treatment assignment, n/N (%)
Placebo
Belimumab 1 mg/kg
Belimumab 10 mg/kg
Baseline SLE characteristics
Mean SELENA-SLEDAI score±SD
≥10, n (%)
BILAG scores, n (%)
≥1 A or 2 B
≥1 A
≥1 B
No A or B
Mean PGA score±SD
Mean SLICC damage index±SD
Mean proteinuria±SD, g/24 h
Anti-dsDNA ≥30 IU/mL, n (%)
ANA ≥1:80, n (%)
Mean IgG±SD, g/L
>16.2 g/L, n (%)
Low C3 (<90 mg/dL), n (%)
Low C4 (<16 mg/dL), n (%)
Corticosteroid use, n (%)
>7.5 mg/d, n (%)
Immunosuppressant use, n (%)
Baseline HRQoL
Mean SF-36 PCS±SD
Mean SF-36 MCS±SD
Mean FACIT-Fatigue score±SD

Responders (n=761)

Non-responders (n=923)

All patients (n=1684)

718 (94.3)
37.3±11.4

867 (93.9)
38.2±11.6

1585 (94.1)
37.8±11.5

218/562 (38.8)
258/559 (46.2)
285/563 (50.6)

344/562 (61.2)
301/559 (53.8)
278/563 (49.4)

NA
NA
NA

10.5±3.4§
483 (63.5)§

9.1±3.9
395 (42.8)

9.7±3.8
878 (52.1)

493 (64.8)+
125 (16.4)
714 (93.8)§
47 (6.2)§
1.5±0.5+
0.7±1.1+
0.44±0.84
517 (67.9)#
696 (91.5)
16.6±6.0
358 (47.0)
311 (40.9)#
395 (51.9)§
668 (87.8)
471 (61.9)+
323 (42.4)§

531 (57.5)
138 (15.0)
812 (88.0)
111 (12.0)
1.4±0.5
0.9±1.3
0.53±0.99
651 (70.5)
870 (94.2)
16.4±6.2
386 (41.8)
447 (48.4)
549 (59.5)
785 (85.0)
505 (54.7)
497 (53.8)

1024 (60.8)
263 (15.6)
1526 (90.6)
158 (9.4)
1.4±0.5
0.8±1.2
0.49±0.93
1168 (69.4)
1566 (93.0)
16.5±6.1
744 (44.2)
758 (45.0)
944 (56.1)
1453 (86.3)
976 (58.0)
820 (48.7)

39.6±9.2*
40.6±10.9
30.9±11.5*

38.6±10.0
41.0±11.6
29.4±12.1

39.1±9.7
40.8±11.3
30.1±11.9

*p<0.05; +p<0.01; #p<0.001; §p<0.0001 (note: p values represent comparison between responders and non-responders from the likelihood
ratio test for categorical data and from the t-test for continuous variables).
ANA, antinuclear antibody; anti-dsDNA, antidouble-stranded DNA; BILAG, British Isles Lupus Assessment Group; C, complement; FACIT,
Functional Assessment of Chronic Illness Therapy; HRQoL, health-related quality of life; IgG, immunoglobulin-G; MCS, Mental Component
Summary; NA, not applicable; PCS, Physical Component Summary; PGA, Physician’s Global Assessment; SELENA-SLEDAI, Safety of
Estrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index; SF-36, Medical Outcomes Survey Short Form; SLE,
Systemic Lupus Erythematosus; SLICC, Systemic Lupus International Collaborating Clinics; SRI, SLE Responder Index.

improvements in PGA scores in all patients as well as
those with no worsening of PGA scores at Week 52 were
greater among responders versus non-responders (both
p<0.001; 49.3% of non-responders had no worsening at
Week 52). Responders had greater improvements in
PGA than non-responders as early as Week 4 and this
continued through Week 52 (ﬁgure 1A).
SRI response as a predictor of BILAG response
To evaluate whether a SRI response at Week 52 predicted improvement in BILAG items present at baseline,
an analysis was performed that required a responder to
have met SRI response criteria and to have had ≤1
BILAG B score present at Week 52. At baseline 64.8% of
SRI responders and 57.5% of non-responders had >1
BILAG B or ≥1 A score. At Week 52 91.9% of SRI
responders had ≤1 BILAG B score (table 2) compared
with 35.9% of SRI non-responders ( p<0.001).

SLE flare index
The risks of any ﬂare and severe ﬂare were lower in SRI
responders (42% (HR 0.58; 95% CI 0.52 to 0.65;
p<0.001) and 87% (0.13; 0.09 to 0.17; p<0.001), respectively: ﬁgure 1B).
Corticosteroid use
Approximately 62% of SRI responders and 55% of nonresponders received a prednisone (or equivalent) dose
>7.5 mg/d at baseline (table 1). Of these patients, more
responders than non-responders had dose reductions
≥25% to <7.5 mg/d at Week 52 (25.5% vs 16.4%;
p<0.001), and fewer responders who received prednisone ≤7.5 mg/d at baseline had dose increases to
>7.5 mg/d at Week 52 (4.1% vs 21.3%). Over time,
fewer SRI responders than non-responders had increases
in prednisone dose >7.5 mg/d, with a difference beginning at Week 12 (ﬁgure 1C). The proportion of non-
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Clinical measures
SELENA-SLEDAI, n (%)
≥4-point reduction
≥7-point reduction
Mean no. of organ domains with improvement, per patient (SE)§
BILAG
SELENA-SLEDAI
No new BILAG A score and ≤1 new B score, n (%)
Mean % change in PGA score from baseline in all patients (SE)
Furie R, Petri MA, Strand V, et al. Lupus Science & Medicine 2014;1:e000031. doi:10.1136/lupus-2014-000031

Mean % change in PGA score from baseline in patients with no worsening (SE)
≥0.3-point increase, n††
Corticosteroid dose, n (%)
Dose decrease to ≤7.5 mg/d from >7.5 mg/d at baseline††
Dose increase to >7.5 mg/d from ≤7.5 mg/d at baseline‡‡
SFI flare, n (%)
Any
Severe
Serological measures
Anti-dsDNA antibodies
Median % change in patients positive (≥30 IU/L) at baseline (Q1, Q3)¶¶
Normalisation in patients positive at baseline, n (%)¶¶
C3
Median % change in patients with low C3 (<90 mg/dL) at baseline (Q1, Q3)¶¶
Normalisation in patients with low C3 at baseline, n (%)¶¶
C4
Median % change (Q1,Q3) in patients with low C4 (<16 mg/dL) at baseline
(Q1, Q3)¶¶
Normalisation in patients with low C4 at baseline, n (%)¶¶

SRI responders (n=761)

SRI non-responders
(n=923)

p Value

Adjusted
p value*

761 (100)
307 (40.3)

35 (3.8)
12 (1.3)

<0.001†
<0.001†

<0.001‡
<0.001‡

1.45 (0.03)
2.00 (0.03)
699 (91.9)
−58.3 (1.17)
(n=761)
−58.3 (1.17) 761

0.40 (0.02)
0.39 (0.02)
331 (35.9)
−13.7 (2.03)
(n=923)
−34.9 (1.75) 455

<0.001¶
<0.001¶
<0.001†
<0.001¶

<0.001**
<0.001**
<0.001**
<0.001‡

<0.001¶

<0.001‡

120/471 (25.5)
12/290 (4.1)

70/505 (13.9)
89/418 (21.3)

<0.001†
<0.001†

<0.001‡
<0.001‡

532 (69.9)

763 (82.7)

<0.001†††

47 (6.2)

269 (29.1)

HR 0.58 95% CI 0.52 to
0.65 <0.001§§
HR 0.13 95% CI 0.09
to 0.17 <0.001§§

−34.2 (−57.04, −0.50)
(n=434)
69/479 (14.4)

−26.1 (−50.81, 6.76)
(n=479)
47/434 (10.8)

0.01***

0.129**

0.10†

0.243‡

14.5 (1.25, 35.46)
(n=292)
89/292 (30.5)

9.0 (−4.88, 26.51)
(n=293)
74/293 (25.3)

0.001***

0.009**

0.16†

0.044‡

40.0 (13.33, 81.82)
(n=361)
134/361 (37.1)

28.6 (0.00, 63.64)
(n=379)
112/379 (29.6)

0.003***

0.049**

0.03†

0.013‡

<0.001†††

*The analysis was adjusted for the baseline value for each listed parameter using the following methods of analysis.
†Likelihood ratio test.
‡logistic regression test.
§Improved from British Isles Lupus Assessment Group (BILAG) A to B score or better, or from B to C score or better; dropout=failure.
¶2-sample t test.
**Analysis of covariance test.
††Last observation carried forward.
‡‡Dropout=failure.
§§Log-rank test.
¶¶Based on modified Systemic Lupus Erythematosus (SLE) Responder Index (SRI) analysis that excluded anti-dsDNA and complement items from determination of 4-point decrease in Safety
of Estrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index (SELENA-SLEDAI) component of SRI; includes patients with data available at Week 52/primary visit.
***Wilcoxon test.
†††Cox test.
anti-dsDNA, antidouble-stranded DNA; C, complement; PGA, Physician’s Global Assessment; Q, quartile; SFI, SLE Flare Index.
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Table 2 Changes in clinical and serological measures from baseline in SRI responders versus non-responders at Week 52

Epidemiology and outcomes
Figure 1 Comparison of SRI
responders and non-responders.
(A) Mean % change in PGA
score, (B) risk for flare by SFI,
and (C) corticosteroid use over
52 weeks. *p<0.05; +p<0.01;
#
p<0.001. PGA, Physician’s
Global Assessment; SFI, SLE
Flare Index; SRI, Systemic Lupus
Erythematosus (SLE) Responder
Index.

responders with increases in corticosteroid doses rose
continually over the study period, whereas the proportion of responders did not rise after Week 4.
Serological measures
In all, 913 patients were anti-dsDNA-positive, 585 had
low C3 levels (<90 mg/dL) and 740 had low C4 levels
(<16 mg/dL) at baseline. Median anti-dsDNA antibody
levels were lower in SRI responders than in nonresponders at Week 52 (−34.2% vs −26.1%). Of patients
with hypocomplementaemia at baseline, median per
cent increases from baseline C3 and C4 levels were
greater in responders than non-responders (C3: 14.5%
vs 9.0%; C4: 40.0% vs 28.6%). More responders than
non-responders exhibited normalisation of anti-dsDNA
levels (14.4% vs 10.8%). Similarly, normalisation of low
complement levels occurred more often in responders
than in non-responders (C3: 30.5% vs 25.3%; C4: 37.1%

vs 29.6%). Of 542 patients with measurements of circulating CD20 B cell subsets and plasma cell subsets at
baseline and Week 52 in BLISS-76, the per cent reductions in these cell types at Week 52 were numerically
greater in responders (data not shown). This ﬁnding
was driven primarily by the SRI responders in the
belimumab treatment groups who experienced greater
reductions in B cell and plasma cell subsets than
patients treated with standard therapy alone.13
Baseline covariate adjusted multivariate analysis of clinical
and serological parameters
Overall results from the baseline adjusted analysis were
similar to the univariate analysis. There was a greater
response in SRI responders compared with nonresponders, with similar p values for all the disease activity measures, including SELENA-SLEDAI, BILAG, PGA
and SFI ﬂare, as well as reduced corticosteroid use and
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improvement in complement levels. The only differences observed were in the serological parameters. The
% median change and % normalisation of anti-dsDNA
were not signiﬁcantly different between SRI responders
and non-responders; the normalisation of low C3 was
signiﬁcantly greater for SRI responders.

Patient-reported measures: HRQoL and fatigue
SRI responders were more likely to have higher baseline
PCS scores than non-responders ( p<0.05; table 1).
Thresholds for minimum clinically important differences
(MCIDs) from baseline are 2.5 points for the SF-36 PCS
and MCS scores, and are generally considered 5 points
for each of the eight domain scores.14 At Week 52, mean
improvements in SF-36 PCS and MCS scores were greater
in SRI responders versus non-responders (4.9 vs 2.6 and
4.4 vs 1.7, respectively; p<0.001) and exceeded MCID. A
higher percentage of responders reported improvements
≥MCID than non-responders in PCS (59% vs 49%) and
MCS (56% vs 44%). Similarly, improvements in individual
domain scores were greater in SRI responders and
exceeded MCID (all p<0.001). Improvements in nonresponders exceeded MCID for PCS and role-physical,
bodily pain and vitality domain scores. Mean improvements were ≥two-fold greater in responders versus nonresponders in six of eight domains (ﬁgure 2 and see
online supplementary ﬁgure S1); a consistently higher
percentage of responders reported changes ≥MCID than
non-responders in all domain scores (ranging from 54%
vs 42%, respectively, for the role-emotional domain to
65% vs 53%, respectively, for the general health domain).
At Week 52, more than twice as many responders versus
non-responders reported feeling ‘somewhat better’
(76.1% vs 33.5%) and ‘much better’ (33.8% vs 14.6%)
than 1 year ago.
Mean improvements in FACIT-Fatigue scores were
higher in SRI responders than non-responders at Week
52 (5.2 vs 3.0). Improvement in the responder group
exceeded MCIDs of 4 points as deﬁned in patients with

rheumatoid arthritis.15 Greater improvements in
FACIT-Fatigue scores were observed by Week 8 in responders and were sustained through 52 weeks (ﬁgure 3).
These ﬁndings are supported by improvements reported
by responders in the SF-36 vitality domain (10.4 vs 6.5).

DISCUSSION
Although the lupus research community has become
comfortable with SELENA-SLEDAI, BILAG and PGA as
efﬁcacy measures, the same level of understanding does
not exist for the SRI. Therefore, we examined the clinical
meaningfulness of SRI response in patients with active,
autoantibody-positive SLE, irrespective of therapy.
Improvements in a variety of clinical, serological and clinically meaningful changes in patient-reported outcome
measures indicated that a SRI response was associated
with global beneﬁt beyond that measured by the components of the SRI. Overall, reductions in severe ﬂares and
corticosteroid use as well as clinically meaningful and statistically signiﬁcant improvement in patient-reported outcomes correlated with SRI responder status.
While SRI responders would be expected to more frequently meet the SRI criteria (≥4-point improvement)
for SELENA-SLEDAI than non-responders, 40% of
responders in this analysis had improvement of ≥7
points on the SELENA-SLEDAI compared with 1% of
non-responders. The improvement in PGA score in
responders was greater than that achieved in nonresponders, as well as in the subgroup of non-responders
with no worsening in PGA scores, suggesting that SRI
response is associated with a marked improvement in
overall health. This ﬁnding is supported by clinically
meaningful improvements in patient-reported HRQoL
and fatigue, including PCS, MCS and all domain scores
of SF-36, FACIT-Fatigue scores and the SF-36 transition
question. In addition, SRI response was correlated with
higher mean numbers of organ domains with improvement on SELENA-SLEDAI (2.00 vs 0.39) and BILAG
(1.45 vs 0.40), as well as greater reductions in risk of any

Figure 2 Mean change from
baseline in SF-36 domain and
summary scores. #p<0.001.
MCID, minimum clinically
important difference; MCS,
Mental Component Summary;
PCS, Physical Component
Summary; SF-36, Medical
Outcomes Survey Short Form.
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Figure 3 Comparison of SRI responders and
non-responders for change in FACIT-Fatigue score over
52 weeks. *p<0.05; +p<0.01; #p<0.001. FACIT, Functional
Assessment of Chronic Illness Therapy; MCID, minimum
clinically important difference; SRI, Systemic Lupus
Erythematosus (SLE) Responder Index.

ﬂare (42%) and severe ﬂare (87%) over 52 weeks compared with non-responders. SRI response was also associated with lower overall corticosteroid use; nearly twice
as many responders (25.5% vs 14%) with initial prednisone doses >7.5 mg/d were able to reduce corticosteroid
doses, and 4% of responders versus 21% of nonresponders with initial doses ≤7.5 mg/d had a dose
increase at Week 52. These clinical beneﬁts were
observed in SRI responders as early as 8–12 weeks on
study medications and this improvement generally
increased over time. SRI response appeared to be predictive of BILAG response: 92% of patients, irrespective
of SLE therapy, who achieved a SRI response also had
≤1 BILAG B organ score after 1 year of treatment.
Numerous studies have indicated that anti-dsDNA antibodies and low complement levels are associated with
more severe disease and reduced HRQoL,16–22 and the
American College of Rheumatology and European
League Against Rheumatism recommend monitoring
serum C3/C4 and anti-dsDNA.23 24 A SRI response was
associated with a decrease in anti-dsDNA antibodies, and
increases in C3 and C4 levels in patients with low complement levels at baseline compared with non-responders
and more responders had normalisation of these
markers. Improvements in these serological markers have
been associated with reduced risk of severe ﬂare and
greater likelihood of achieving a SRI response, irrespective of therapy.13 Baseline values of B cell and plasma cell
subsets were similar between SRI responders and nonresponders. Although SRI responders generally had
greater reductions in B cell and plasma cell subsets than
non-responders, this was driven by a greater proportion
of SRI responders receiving belimumab treatment, since
belimumab treatment resulted in greater reductions in B
cells and plasma cells than did standard therapy alone.
Other analyses of the BLISS trials have shown that the
beneﬁt of belimumab plus standard therapy over standard therapy was augmented in patients with higher
disease activity, as deﬁned by baseline SELENA-SLEDAI

≥10, low complement levels, anti-dsDNA-positivity, and
corticosteroid treatment, and in patients with
anti-dsDNA-positivity and low complement levels.13 25
Overall, SRI responders were more likely to have
baseline high disease activity similar to the predictors of a
belimumab SRI response. However, corticosteroid treatment was not predictive of a SRI response, whereas
patients receiving prednisone >7.5 mg at baseline were
more likely to have achieved a SRI response. Baseline
serological activity was not associated with an overall
greater likelihood of a SRI response, irrespective of
therapy. This differential response can be partially
explained by patients in the placebo and belimumab
1 mg/kg groups with high serological activity having
lower rates of SRI response (31.7% and 41.5%, respectively) than the overall placebo and 1 mg/kg groups
(38.8% and 46.2%, respectively), whereas the SRI
responses in the 10 mg/kg group were similar in serologically active (51.5%) and all patients in that treatment
group (50.6%).25
The HRQoL beneﬁts in SRI responders support the
association of a SRI response with broad improvements
in SLE disease activity. The impact of SLE on HRQoL is
comparable with or worse than other chronic diseases
(eg, AIDS, rheumatoid arthritis, diabetes, congestive
heart failure).1 21 22 26 Baseline SF-36 PCS and MCS
scores in the BLISS trials reﬂected this high impact of
SLE on HRQoL: compared with mean normative values
of 50 in SF-36 summary scores, mean baseline scores
were 39.1 for PCS and 40.8 for MCS. At Week 52,
improvements from baseline in SF-36 PCS, MCS and all
domain scores were greater in SRI responders and
exceeded MCID for all scores.
Fatigue is one of the most common clinical manifestations of SLE and is associated with poor physical and
Mean
improvements
in
mental
functioning.27
FACIT-Fatigue scores reported by SRI responders were
greater than in non-responders, with changes from baseline exceeding MCID from Weeks 12 to 52 in those
achieving a SRI response at Week 52. However, it should
be noted that a MCID of 4, while valid in patients with
rheumatoid arthritis, has not yet been validated in
patients with SLE. However the MCIDs for SF-36
summary and domain scores were independently validated in SLE and correspond closely to those determined
in rheumatoid arthritis. Reductions in fatigue were conﬁrmed by a greater increase in SF-36 vitality domain
score, consistent with other published data indicating a
high correlation between these measurements.15 28
Finally, three-quarters of responders indicated that they
felt ‘somewhat’ or ‘much better’ than 1 year before compared with a third of non-responders.
Interpretation of these study results is limited by the
post hoc nature of the analyses. In addition, examining
a clinical trial population based on achievement of the
primary end point (SRI at Week 52) eliminates the randomised balance of baseline characteristics in the treatment groups. Baseline characteristics were, however,

Furie R, Petri MA, Strand V, et al. Lupus Science & Medicine 2014;1:e000031. doi:10.1136/lupus-2014-000031

7

Lupus Science & Medicine
generally similar between SRI responders and nonresponders. A baseline covariate adjusted analysis
showed results similar to the unadjusted univariate analysis. Further, there was a greater magnitude of difference in clinical and patient reported outcomes between
these groups than in the baseline characteristics.
Although some individual variables examined were
response criteria that, by deﬁnition, were met by responders, analysis of results for these criteria in nonresponders remains instructive.
CONCLUSIONS
Our results indicate that SRI responses, irrespective of
therapy, are associated with global, clinically meaningful
beneﬁts in patients with active, autoantibody-positive SLE.
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